PMV Pharmaceuticals: Virtual KOL Event to review Phase 1 clinical data on PC14586 – a first-in-class precision oncology investigational therapy targeting TP53 Y220C mutation
About The Event
Join us for a virtual KOL event with PMV Pharmaceuticals, featuring Aparna Parikh, M.D. M.S., Director of the Global Cancer Care Program at Mass General Hospital Cancer Center, who will discuss the updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
The updated PYNNACLE results are being featured in a late breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, also on October 12.
PMV Pharmaceuticals management will provide details on the PC14586 development program as well as a regulatory update. A live question and answer session will follow the formal presentations.